Moderate to Severe Plaque Psoriasis (DBCOND0040433)

Identifiers

Synonyms

Moderate-to-severe Plaque Psoriasis

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Certolizumab pegol	A tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis.	Tumor necrosis factortarget Aldo-keto reductase family 1 member A1enzyme
Ixekizumab	A monoclonal antibody used to treat moderate to severe plaque psoriasis.	Interleukin-17Atarget
Methotrexate	An antineoplastic agent used the treatment of a wide variety of cancers as well as severe psoriasis, severe rheumatoid arthritis, and juvenile rheumatoid arthritis.	Dihydrofolate reductasetarget Aldehyde oxidaseenzyme Methylenetetrahydrofolate reductase (NADPH)enzyme Albumincarrier ATP-binding cassette sub-family C member 3transporter ATP-binding cassette sub-family C member 4transporter Multidrug resistance-associated protein 1transporter Solute carrier family 22 member 6transporter ATP-binding cassette sub-family C member 10transporter Organic anion transporter 3transporter ATP-binding cassette sub-family C member 2transporter ATP-dependent translocase ABCB1transporter Solute carrier organic anion transporter family member 1A2transporter Monocarboxylate transporter 1transporter ATP-binding cassette sub-family C member 11transporter Solute carrier organic anion transporter family member 1B3transporter Solute carrier family 22 member 11transporter Solute carrier organic anion transporter family member 1C1transporter Solute carrier organic anion transporter family member 3A1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Solute carrier family 22 member 7transporter Solute carrier organic anion transporter family member 1B1transporter 6-phosphogluconate dehydrogenase, decarboxylatingenzyme Proton-coupled folate transportertransporter Folylpolyglutamate synthase, mitochondrialenzyme Gamma-glutamyl hydrolaseenzyme Dihydrofolate reductaseenzyme Thymidylate synthaseenzyme Bifunctional purine biosynthesis protein ATICenzyme Solute carrier organic anion transporter family member 4C1transporter Reduced folate transportertransporter Folate receptor alphatransporter Cytochrome P450 3A4enzyme Thymidylate synthasetarget Bifunctional purine biosynthesis protein ATICtarget Folate receptor betatransporter Solute carrier family 15 member 1transporter Proton-coupled amino acid transporter 1transporter Carboxypeptidase G2enzyme Proton-coupled folate transportertarget Reduced folate transportertarget
Mometasone furoate	A corticosteroid used to treat asthma, allergic rhinitis, nasal congestion, nasal polyps, dermatitis, and pruritus.	Glucocorticoid receptortarget Cytochrome P450 2C8enzyme Progesterone receptortarget Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme
Tildrakizumab	An interleukin-23 antagonist used to treat moderate to severe plaque psoriasis.	Interleukin-23target Cytochrome P450 4A11enzyme

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06258668	Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea	Deucravacitinib	Not Available	Not Available	recruiting
NCT03710681	A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque Psoriasis	Vunakizumab	treatment	1	unknown_status
NCT04612699	A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis	Jaktinib	treatment	2	active_not_recruiting
NCT05787236	A Study of Moderate-to-severe Plaque Psoriasis Patients Response to Secukinumab Treatment in Real-world Setting	No drug interventions	Not Available	Not Available	completed
NCT04839016	Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis	Vunakizumab	treatment	3	unknown_status
NCT06142357	Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis	No drug interventions	Not Available	Not Available	recruiting
NCT06182384	A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices	Vunakizumab	treatment	1	completed
NCT03146247	Analysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients	Apremilast	other	4	withdrawn
NCT03412747	A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis	Adalimumab Bimekizumab	treatment	3	completed
NCT05342428	Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis	No drug interventions	other	1	completed
NCT01401452	Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities	No drug interventions	Not Available	Not Available	completed
NCT05020249	A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis	Bimekizumab	treatment	3	completed
NCT06425549	A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis	Bimekizumab Ustekinumab	treatment	3	recruiting
NCT06506916	A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis	Bimekizumab	treatment	3	not_yet_recruiting
NCT04718896	A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis	Bimekizumab	treatment	2	active_not_recruiting
NCT01644396	An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation	Adalimumab	treatment	4	completed
NCT01748539	A Phase 2 Clinical Study of KHK4827	Brodalumab	treatment	2	completed
NCT04999839	Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis	Zasocitinib	treatment	2	completed
NCT02607774	Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis	Midazolam Secukinumab	basic_science	1	completed
NCT05258331	Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis	No drug interventions	treatment	1	recruiting
NCT00626002	Open Label Continuation Study in Moderate to Severe Psoriasis	Briakinumab	treatment	3	completed
NCT05155098	2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis	No drug interventions	Not Available	Not Available	active_not_recruiting
NCT04614298	A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis	Brodalumab	treatment	4	withdrawn
NCT02982005	A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea	Brodalumab	treatment	3	completed
NCT01077232	Documentation of Humira in Psoriasis Patients in Routine Clinical Practice	No drug interventions	Not Available	Not Available	completed
NCT01555606	An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis	No drug interventions	Not Available	Not Available	completed
NCT06109818	Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis	No drug interventions	treatment	2	recruiting
NCT04367441	Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects	No drug interventions	treatment	1	unknown_status
NCT01622348	Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis	No drug interventions	other	2	completed
NCT04566666	To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis	No drug interventions	treatment	2	recruiting
NCT01202565	Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice	No drug interventions	Not Available	Not Available	completed
NCT02660580	MSB11022 in Moderate to Severe Chronic Plaque Psoriasis	Adalimumab	treatment	3	completed
NCT00710580	Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis	Briakinumab Etanercept	treatment	3	completed
NCT01260844	Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.	Briakinumab	Not Available	1	withdrawn
NCT03390101	An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis	Netakimab	treatment	3	completed
NCT02713295	A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece	No drug interventions	Not Available	Not Available	completed
NCT04967508	A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis	Ustekinumab	treatment	3	completed
NCT01708603	P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis	Brodalumab Ustekinumab	treatment	3	terminated